Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Mutlay Sayan, MD

Advertisement

Articles by Mutlay Sayan, MD

Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.

Bruce Haffty, MD, and Mutlay Sayan, MD, on Radiation Oncology's Next Frontier and Mentorship

ByGina Mauro,Bruce G. Haffty, MD,Mutlay Sayan, MD
October 2nd 2026

Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on CancerNetwork

    1

    FDA Grants Priority Review to Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastric/GEJ Cancers

    2

    BELLWAVE Program for Nemtabrutinib Discontinued After Phase 3 CLL/SLL Trial

    3

    BHV-1530 Shows Responses in FGFR3-Altered Urothelial and Head and Neck Cancers

    4

    ET Adherence Raises Cardiometabolic Risk, Improves Survival in HR+ Breast Cancer

    5

    A New Era of Personalized Cancer Therapeutics at ESMO

    • About
    • Advertise
    • CureToday.com
    • OncLive.com
    • OncNursingNews.com
    • TargetedOnc.com
    • Editorial
    • Contact
    • Terms and Conditions
    • Privacy
    • Do Not Sell My Personal Information
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    Brand Logo

    © 2026 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us